Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 5/20 | 0.37 |
| ▸ | HTR1D | P28221 | 5/20 | 0.37 |
| ▸ | HTR1B | P28222 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17738485 | 0.79 | TRPV1 (0.45) | TRPV1 | |
| SCHEMBL17738540 | 0.79 | ALDH1A1 (0.44) | TRPV1LRRK2IDO1NOS1 | |
| SCHEMBL30146781 | 0.77 | ROCK2 (0.43) | TRPV1LRRK2IDO1NOS1AXL | |
| SCHEMBL10274947 | 0.72 | DRD2 (0.45) | HTR1AKCNH2 | |
| SCHEMBL15515417 | 0.72 | NOS1 (0.49) | TRPV1IDO1NOS1AXL | |
| SCHEMBL28458675 | 0.71 | TRPV1 (0.49) | TRPV1IDO1NOS1AXL | |
| SCHEMBL17738996 | 0.71 | TRPV1 (0.40) | TRPV1IDO1NOS1AXL | |
| SCHEMBL12842830 | 0.70 | HTR6 (0.58) | HTR1AHTR1DHTR1BNOS1AXL | |
| SCHEMBL17739188 | 0.70 | KDM4E (0.55) | TRPV1 | |
| SCHEMBL17477187 | 0.69 | DRD4 (0.38) | LRRK2KCNH2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590086-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590086-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | TRPV1 3090/4885LRRK2 1105/4885IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.